Fore Capital’s Pfizer PFE Stock Holding History

Fore Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-60,000	Closed	-$2.35M	–	65
2021 Q2	$2.35M	Sell	60,000 -340,000	-85%	-$13.2M	0.72%	24
2021 Q1	$14.5M	Buy	+400,000	New	+$14.2M	2.69%	8

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fore Capital's PFE Position: Q3 2021 in Review

Fore Capital sold out of Pfizer (PFE) in Q3 2021, closing a stake of 35,000 shares — an estimated $1.37M sold.

Fore Capital first reported a position in PFE in Q4 2020 and held it in 2 quarters. The position peaked at $1.37M in Q2 2021. 2,805 funds tracked by Wall St. Rank hold PFE as of Q3 2021.

Fore Capital reported no remaining Pfizer position as of Q3 2021 after selling out during the quarter.
Fore Capital sold 35,000 Pfizer shares in Q3 2021, an estimated $1.37M.
Fore Capital first reported a position in Pfizer in Q4 2020 and held it in 2 quarters.
Fore Capital's Pfizer position peaked at $1.37M in Q2 2021.
2,805 funds tracked by Wall St. Rank held Pfizer as of Q3 2021.

Based on Fore Capital's 13F filing for Q3 2021, filed 12 Nov 2021.